2022
Artificial Intelligence in Breast Cancer Screening
Potnis K, Ross J, Aneja S, Gross C, Richman I. Artificial Intelligence in Breast Cancer Screening. JAMA Internal Medicine 2022, 182: 1306-1312. PMID: 36342705, PMCID: PMC10623674, DOI: 10.1001/jamainternmed.2022.4969.Peer-Reviewed Original Research
2014
Decision-making and cancer screening: A qualitative study of older adults with multiple chronic conditions
Gross CP, Fried TR, Tinetti ME, Ross JS, Genao I, Hossain S, Wolf E, Lewis CL. Decision-making and cancer screening: A qualitative study of older adults with multiple chronic conditions. Journal Of Geriatric Oncology 2014, 6: 93-100. PMID: 25544380, DOI: 10.1016/j.jgo.2014.12.001.Peer-Reviewed Original ResearchConceptsCancer screening decisionsCancer screeningChronic conditionsCancer statusEducational promptsOlder personsMultiple chronic conditionsScreening decisionsDirect health benefitsMedical conditionsOverall healthOlder adultsThematic saturationHealth benefitsLife expectancyIndependent readersHealth scenarioMost respondentsScreeningAdultsAgeQualitative studySample sizeStatusMedicationsEvolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic Implications
Killelea BK, Long JB, Chagpar AB, Ma X, Wang R, Ross JS, Gross CP. Evolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic Implications. Journal Of The National Cancer Institute 2014, 106: dju159. PMID: 25031307, PMCID: PMC4155428, DOI: 10.1093/jnci/dju159.Peer-Reviewed Original ResearchConceptsEnd Results-MedicareBreast cancer stageCohort of womenEarly-stage tumorsBreast cancer screeningAdjunct imagingSignificant changesCancer screeningCancer stageIncidence rateBreast cancerAdjunct procedureOlder womenMedicare populationMedicare beneficiariesClinical practiceComputer-aided detectionPoisson regressionNational feeCohortBreast ultrasoundWomenEarlier cohortsLater cohortsMedicare spending
2013
The cost implications of prostate cancer screening in the Medicare population
Ma X, Wang R, Long JB, Ross JS, Soulos PR, Yu JB, Makarov DV, Gold HT, Gross CP. The cost implications of prostate cancer screening in the Medicare population. Cancer 2013, 120: 96-102. PMID: 24122801, PMCID: PMC3867600, DOI: 10.1002/cncr.28373.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCohort StudiesEarly Detection of CancerHumansKallikreinsMaleMedicareNeoplasm StagingProstate-Specific AntigenProstatic NeoplasmsSEER ProgramUnited StatesConceptsProstate cancerScreening costsAnnual screening costsPopulation-based cohortProstate cancer screeningHospital referral region levelMale Medicare beneficiariesProstate-specific antigenCancer screeningLowest quartileHRR levelMedicare populationMedicare beneficiariesOlder menNational feeCancerService Medicare programCancer diagnosisMenQuartilePSACost implicationsAnnual expenditureMedicare programBiopsy
2012
Impact of the 2008 US Preventive Services Task Force Recommendation to Discontinue Prostate Cancer Screening Among Male Medicare Beneficiaries
Ross JS, Wang R, Long JB, Gross CP, Ma X. Impact of the 2008 US Preventive Services Task Force Recommendation to Discontinue Prostate Cancer Screening Among Male Medicare Beneficiaries. JAMA Internal Medicine 2012, 172: 1601-1603. PMID: 22987029, PMCID: PMC3597450, DOI: 10.1001/archinternmed.2012.3726.Peer-Reviewed Original ResearchMeSH KeywordsAdvisory CommitteesAgedEarly Detection of CancerGuidelines as TopicHumansIncidenceMaleMass ScreeningMedicareProstatic NeoplasmsRetrospective StudiesUnited States